Clinical trial NCT00691210
Conditions: Hodgkin's Disease Non-Hodgkin's Lymphoma
Keywords: Hodgkin's Disease Non-Hodgkin's Lymphoma
Sponsor: Columbia University
Start date: 2008-06-01; Completion date: 2015-03-01
Enrollment: 40 participants; Allocation: NON_RANDOMIZED; Intervention model: SINGLE_GROUP

Brief summary:
The purpose of this study is to test the safety of a combination of two anticancer medicines, called vorinostat and etoposide, with a high dose of a vitamin called niacinamide. These medications will be tested at different dose levels. The investigators want to find out what effects, good and/or bad, it has on patients and their recurrent lymphoma. The first two drugs, vorinostat and niacinamide, suppress survival signals that lymphoma cells depend on. The third drug, etoposide can kill sensitive lymphoma cells alone or in combination with other chemotherapy drugs. Vorinostat is an anticancer agent that been approved by the Food and Drug Administration for use in cutaneous T-cell lymphoma. It is being evaluated in this study in combination with other anticancer medicines for use in other types of lymphoma. Vorinostat's use in combination with anticancer regimens is experimental. Niacinamide is a vitamin that is investigational or experimental when given at high doses as an anticancer agent. Niacinamide has not yet been approved by the Food and Drug Administration for use in lymphoma. Etoposide has been approved by the Food and Drug Administration for use in aggressive non-Hodgkin's lymphoma. However, the way it will be given in this clinical study is experimental.

Detailed description:
Subjects will be treated with vorinostat administered orally with daily dosing for 14 days of a 21-day treatment cycle in combination with niacinamide administered orally for 14 days in 21-day treatment cycle and etoposide administered intravenously on days 8,9 and 10 of a 21-day treatment cycle. Etoposide dose will be escalated until maximum tolerated dose (MTD) is determined.

Arms: arm 1: Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg arm 2: Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg arm 3: Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg arm 4: Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg arm 5: Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg arm 6: Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2 arm 7: Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2 arm 8: Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2
Interventions: intervention 1: Vorinostat intervention 2: Niacinamide intervention 3: Etoposide
Intervention descriptions: intervention 1: Dose escalation scheme (400 mg)

Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells. intervention 2: Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)

Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer. intervention 3: Dose escalation scheme (0, 25, 50, 100 mg/m2)

Etoposide is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as a "plant alkaloid" and "topoisomerase II inhibitor."

Protocol documents: